Markers to define ischemia: Are they ready for prime time use in patients with acute coronary syndromes?

Current Cardiology Reports

Volumn 6, Issue 4, 2004, Pages 253-258

  Adams, Jesse ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALBUMIN; ANTITHROMBOCYTIC AGENT; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CD40 ANTIGEN; CHEMOTACTIC FACTOR; CHOLINE; EPTIFIBATIDE; FATTY ACID; GLUTATHIONE PEROXIDASE; HORMONE PRECURSOR; MYELOPEROXIDASE; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TROPONIN I; TROPONIN T;

CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE MARKER; ELECTROCARDIOGRAPHY; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; PATHOPHYSIOLOGY; REVIEW; SENSITIVITY AND SPECIFICITY; THORAX PAIN; UNSTABLE ANGINA PECTORIS;

EID: 5444268795     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-004-0072-1     Document Type: Review

References (27)

1. Hamm CW, Braunwald E: A classification of unstable angina revisited. Circulation 2000, 102: 118-122.
2. Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina J Am Coll Cardiol 2000, 36: 970-1062.
3. Pope JH Selker HP: Diagnosis of acute cardiac ischemia. Emerg Med Clin North Am 2003, 21: 27-59.
4. Selker HP, Zalenski RJ, Antman EM, et al.: An evaluation of technologies for identifying acute cardiac ischemia in the emergency department: a report from a National Heart Attack Alert Program working group. Ann Emerg Med 1997, 29: 13-87.
5. Apple FS, Quist HE, Doyle PJ, et al.: Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003, 49: 1331-1336.
6. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105: 1135-1143.
7. Liuzzo G, Biasucci LM, Rebuzzi AG, et al.: Plasma protein acute-phase response in unstable angina is not induced by ischemic injury. Circulation 1996, 94: 2373-2380.
8. Sabatine MS, Morrow DA, de Lemos JA, et al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002, 105: 1760-1763.
9. Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000, 36: 959-969.
10. Antman EM, Tanasijevic MJ, Thompson B, et al.: Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996, 335: 1342-1349.
11. Jaffe AS: Testing the wrong hypothesis: the failure to recognize the limitations of troponin testing. J Am Coll Cardiol 2001, 38: 999-1001.
12. McDonough JL, Labugger R, Van Eyk JE: Prepare to meet your markers: making the most of troponin degradation. In Markers in Cardiology: Current and Future Clinical Applications. Edited by Adams JE, Apple FS, Jaffe AS, Wu AHB. Armonk, NJ: Futura; 2001:13-21.
13. Feldman L, Rouleau C: Troponin I inhibits endothelial cell proliferation by interaction with the cell's bFGF receptor. Microvasc Res 2002, 63: 41-49.
14. Moses MA, Wiederschain D, Wu I, et al.: Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl Acad Sci U S A 1999, 96: 2645-2650.
15. Schonbeck U, Varo N, Libby P, et al.: Soluble CD40L and cardiovascular risk in women. Circulation 2001, 104: 2266-2268.
16. Varo N, de Lemos JA, Libby P, et al.: Soluble CD40L risk prediction after acute coronary syndromes. Circulation 2003, 108: 1049-1052.
17. Heeschen C, Dimmler S, Hamm CW, et al.: Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003, 348: 1104-1111.
18. Danne O, Mockel M, Lueders C, et al.: Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003, 91: 1060-1067.
19. Blankenberg S, Rupprecht HJ, Bickel C, et al.: Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003, 349: 1605-1613.
20. Singa MK, Roy D, Gaze DC, et al.: Role of "ischemia modified albumin," a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary artery syndromes. Emerg Med J 2004, 21: 29-34.
21. Brennan ML, Penn MS, Van Lente F, et al.: Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003, 349: 1595-1604.
22. Baldus S, Heeschen C, Meinertz T, et al.: for the CAPTURE investigators: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003, 108: 1440-1445.
23. James SK, Lindahl B, Siegbahn A, et al.: N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease. Circulation 2003, 108: 275-281.
24. Morrow DA, Braunwald E: Future of biomarkers in acute coronary syndromes. Circulation 2003, 108: 250-252.
25. Lund J, Qin QP, Ilva T, et al.: Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003, 108: 1924-1926.
26. Kleinfeld AM, Kleinfeld KJ, Adams JE: Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute myocardial infarction in patient samples from the TIMI II trial. J Am Coll Cardiol 2002, 39: 413A.
27. Adams JE, Kleinfeld A, Roe M, et al.: Measurement of levels of unbound free fatty acid allows the early identification of patients with acute coronary syndromes [abstract]. Circulation 2002, 105: 1-324.